Skip to the content
  • Suomeksi
  • About Us
    • > Our role
    • > BoD and management
    • > Sustainability
  • Pharma Sector
    • > Feasibilities and inquiries
    • > Research archive
    • > References for post-licensure studies
  • Newsfeed
  • Contacts
  • Suomeksi

News
28.08.2023

Studying vaccines for pneumococcal disease

pneumococcal disease, pneumococcal vaccines, pragmatic field trials, real-world data

FVR – Finnish Vaccine Research has a team of specialists who have studied pneumococcal disease over several decades. In addition to clinical vaccine trials conducted at our ten research clinics, we specialize in phase 4 vaccine effectiveness and safety studies based on real-world data and use national health registers to study the burden of vaccine-preventable diseases, their complications, and the healthcare resources they require in different population groups. These studies help evaluate vaccines for national vaccination programs, for example.

FVR also conducts large-scale pragmatic field trials in collaboration with public healthcare providers. These can involve several tens of thousands of participants. Finland offers excellent opportunities for conducting extensive vaccine studies, thanks to high quality Population Information System and national health registers.

Arto Palmu, Chief Research Officer, explains.

Please accept the Marketing cookies to watch this video.

LOOKING FOR A PARTNER IN VACCINE RESEARCH?

PLEASE CONTACT info@fvr.fi FOR GENERAL INQUIRIES OR OUR BUSINESS UNIT HEADS DIRECTLY >>

  • About Us
    • Our role
    • BoD and management
    • Sustainability
  • Pharma Sector
    • Feasibilities and inquiries
    • Research archive
    • References for post-licensure studies
  • Newsfeed
  • Contacts

FVR - Finnish Vaccine Research
Peltokatu 26, 33100 Tampere, Finland
info@fvr.fi Business ID FI32566594

  • About cookies

© Copyrights 2022 FVR – Finnish Vaccine Research